2seventy bio, Inc. (TSVT)
NASDAQ: TSVT · Real-Time Price · USD
4.985
+0.005 (0.10%)
Apr 28, 2025, 4:00 PM EDT - Market closed
2seventy bio Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for 2seventy bio stock have an average target of 6.50, with a low estimate of 5.00 and a high estimate of 11. The average target predicts an increase of 30.39% from the current stock price of 4.99.
Analyst Consensus: Buy
* Price targets were last updated on Mar 14, 2025.
Analyst Ratings
The average analyst rating for 2seventy bio stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 1 | 1 | 1 | 1 | 0 | 0 |
| Hold | 5 | 5 | 5 | 5 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $6 → $5 | Hold | Maintains | $6 → $5 | +0.30% | Mar 14, 2025 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $9 → $5 | Buy → Hold | Downgrades | $9 → $5 | +0.30% | Mar 11, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $7 → $6 | Hold | Maintains | $7 → $6 | +20.36% | Jul 29, 2024 |
| Wedbush | Wedbush | Hold Reiterates $5 | Hold | Reiterates | $5 | +0.30% | Jun 27, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $12 → $11 | Strong Buy | Maintains | $12 → $11 | +120.66% | May 9, 2024 |
Financial Forecast
Revenue This Year
69.85M
from 37.86M
Increased by 84.48%
Revenue Next Year
76.62M
from 69.85M
Increased by 9.69%
EPS This Year
-0.47
from -1.10
EPS Next Year
-0.24
from -0.47
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 94.4M | 109.3M | 97.0M | ||
| Avg | 69.8M | 76.6M | 80.9M | ||
| Low | 52.5M | 53.3M | 65.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 149.3% | 56.5% | 26.6% | ||
| Avg | 84.5% | 9.7% | 5.6% | ||
| Low | 38.7% | -23.7% | -15.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.22 | 0.17 | 0.35 | ||
| Avg | -0.47 | -0.24 | 0.28 | ||
| Low | -0.86 | -0.76 | 0.21 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.